XVIVO Perfusion AB (publ) has carried out a primary issuance of shares of approximately SEK 440 million. The subscription price was determined through an accelerated book-building procedure. 

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. The company's solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents.

Carnegie Investment Bank and DNB Markets acted as Joint Bookrunners. Baker McKenzie acted as legal advisor to the banks with an international capital markets team consisting of Joakim Falkner, Olof Larsson and Sophie Gidlund in Stockholm as well as Adam Farlow and Charles Farnsworth in London.
Explore Our Newsroom